Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design

BACKGROUND: Chronic active antibody-mediated rejection (AMR) is a major cause of graft loss with no approved drugs for its treatment. Currently, off-label regimens are used, reflecting the high unmet need for effective therapies based on well-controlled trials. Clazakizumab is a high-affinity, human...

Descripción completa

Detalles Bibliográficos
Autores principales: Nickerson, Peter W., Böhmig, Georg A., Chadban, Steve, Kumar, Deepali, Mannon, Roslyn B., van Gelder, Teun, Lee, James C., Adler, Scott, Chong, Edward, Djamali, Arjang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772593/
https://www.ncbi.nlm.nih.gov/pubmed/36550562
http://dx.doi.org/10.1186/s13063-022-06897-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772593/
https://www.ncbi.nlm.nih.gov/pubmed/36550562
http://dx.doi.org/10.1186/s13063-022-06897-3

Ejemplares similares